-transparent.png){kind=logo}
The effects of the long-acting beta 2-agonist salmeterol on early and late phase airways events provoked by inhaled allergen were assessed in a group of atopic asthmatic patients. In a placebo-controlled study, salmeterol 50 micrograms inhaled before allergen challenge ablated both the early and late phase of allergen-induced bronchoconstriction over a 34 h time period. Salmeterol also completely inhibited the allergen-induced rise in non-specific bronchial responsiveness over the same time period. These effects were shown to be unrelated to prolonged bronchodilatation or functional antagonism. These data suggest novel actions for topically active long-acting beta 2-agonists in asthma that extend beyond their protective action on airways smooth muscle.
O P Twentyman, and
J P Finnerty, and
A Harris, and
J Palmer, and
S T Holgate
November 1991,
Chest,
O P Twentyman, and
J P Finnerty, and
A Harris, and
J Palmer, and
S T Holgate
November 1995,
The European respiratory journal,
O P Twentyman, and
J P Finnerty, and
A Harris, and
J Palmer, and
S T Holgate
July 1994,
International journal of clinical pharmacology and therapeutics,
O P Twentyman, and
J P Finnerty, and
A Harris, and
J Palmer, and
S T Holgate
May 2002,
The European respiratory journal,
O P Twentyman, and
J P Finnerty, and
A Harris, and
J Palmer, and
S T Holgate
March 2001,
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology,
O P Twentyman, and
J P Finnerty, and
A Harris, and
J Palmer, and
S T Holgate
August 1993,
Respiratory medicine,
O P Twentyman, and
J P Finnerty, and
A Harris, and
J Palmer, and
S T Holgate
October 1997,
The European respiratory journal,
O P Twentyman, and
J P Finnerty, and
A Harris, and
J Palmer, and
S T Holgate
September 2007,
Chest,
O P Twentyman, and
J P Finnerty, and
A Harris, and
J Palmer, and
S T Holgate
May 1994,
Respiratory medicine,
O P Twentyman, and
J P Finnerty, and
A Harris, and
J Palmer, and
S T Holgate
July 1998,
Indian pediatrics,
